A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Debiopharm Group
- 07 Aug 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 23 Jun 2012 Company added in the association field as reported by EudraCT.
- 21 Apr 2012 European Clinical Trials Database reports trial status as recruting in France and Spain; planned patient number is 272.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History